Skip to content

Early-bird registration discount for 2023 Annual Ataxia Conference ending soon. LEARN MORE!

National Ataxia Foundation

Accelerate!

Case Study

A Continuous Effort Towards Treatment of SCA3

Written by Dr. Jorge Diogo Da Silva Edited by Dr. David Bushart How one research group assessed whether Rivastigmine, a Parkinson’s Disease drug, might have a role in treating SCA3 Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is the most common inherited ataxia worldwide. As with Read More…

Translate »

Are you ready for fun and learning at the largest Ataxia conference of the year?

2023 Annual Ataxia Conference: Partnering for Progress

Join us to connect, learn, and take action toward accelerating treatment development!